Cubist Pharmaceuticals, Inc. · Lexington, MA United States ·(NASDAQ (GS): CBST)

Fighting infection is a modern art form at Cubist Pharmaceuticals. The company is developing antimicrobial agents that aim to treat drug-resistant infections typically found in hospitals and other health care institutions. Its flagship product Cubicin is an intravenous antibiotic that is FDA-approved to fight staph infections of the skin and blood; it has also received regulatory approval in Europe and a handful of non-European countries to treat certain kinds of infections. Cubist markets the drug in the US using its own sales force. It has agreements with numerous other firms to develop and market the drug internationally; its partners include Novartis for Europe, Merck for Japan, and AstraZeneca for China. To read the full description, subscribe now.